Industry
LYPHE Group launches industry-first patient representative board
The board aims to ensure that patient’s voices are heard in the industry.
In an industry first, LYPHE is bringing patients to the table to explore how to improve the patient experience across the organisation – and the wider industry.
Registration is now open for the company’s newly created Patient Representative Board, which will focus on patient concerns and issues in the medical cannabis industry.
It will be formed of independent patients from across the UK, Channel Islands and Isle of Man, as well as representatives from patient groups and charities.
Since the rescheduling of medical cannabis in November 2018, LYPHE has been a key player in patient access, with the large majority of patients using its clinical services and dispensary to obtain medication.
The teething pain and successes of the global medical cannabis industry have been well documented by commentators and patients alike.
Announcing the news, LYPHE said the industry’s first Patient Representative Board would ensure patient voices are heard.
Meetings will be held monthly, and feedback from the sessions will be used to further explore how to improve the patient experience.
By working together, LYPHE hopes to bring about changes that will benefit the wider patient community, as well as shape the organisation’s future direction.
Discussing the initiative, LYPHE Group Managing Director Jonathan Nadler, said: “I’m delighted LYPHE is taking the initiative in working closely with patients. We want to build a stronger, more sustainable industry whilst continuing our journey for full patient access.
“The issues that impact our business, and the medical cannabis industry, ultimately impact our patients, which is why improving transparency with patient groups is vital.”
For more information on how to apply visit www.lyphegroup.com.featured
Applicants or patient groups can register their interest by emailing their details along with reasons why they would like to join the Board via the contact form.
Membership will be limited to a total of 12 representatives in addition to the two chairs.
-
News6 months agoUK government accepts ACMD recommendations for CBD products
-
News6 months agoEurope’s first legal cannabis dispensaries to open under sixth Swiss pilot
-
News6 months agoUK government to permit electronic prescribing of cannabis medicines
-
Science5 months agoMedical cannabis doesn’t impair cognitive function – study
-
Industry5 months agoFirst Jersey-grown medicinal cannabis product to hit UK market
-
News6 months agoFive years of medical cannabis, five NHS prescriptions – how did we get here?
-
Medical cannabis6 months agoAlzheimer’s and medical cannabis: a new hope for patients?
-
News5 months agoJapan takes major step towards cannabis reform
